- Home
- PAX vs IMCR Comparison
PAX vs IMCR Comparison
Compare PAX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAX
- IMCR
- Stock Information
- Founded
- PAX 1988
- IMCR 2008
- Country
- PAX Cayman Islands
- IMCR United Kingdom
- Employees
- PAX N/A
- IMCR N/A
- Industry
- PAX Investment Managers
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAX Finance
- IMCR Health Care
- Exchange
- PAX Nasdaq
- IMCR Nasdaq
- Market Cap
- PAX 1.8B
- IMCR 1.7B
- IPO Year
- PAX 2021
- IMCR 2021
- Fundamental
- Price
- PAX $11.92
- IMCR $32.03
- Analyst Decision
- PAX Strong Buy
- IMCR Buy
- Analyst Count
- PAX 1
- IMCR 13
- Target Price
- PAX $14.00
- IMCR $68.73
- AVG Volume (30 Days)
- PAX 633.3K
- IMCR 238.6K
- Earning Date
- PAX 11-05-2024
- IMCR 11-06-2024
- Dividend Yield
- PAX 5.03%
- IMCR N/A
- EPS Growth
- PAX N/A
- IMCR N/A
- EPS
- PAX 0.42
- IMCR N/A
- Revenue
- PAX $328,717,000.00
- IMCR $296,312,000.00
- Revenue This Year
- PAX $1.43
- IMCR $28.88
- Revenue Next Year
- PAX $32.56
- IMCR $12.61
- P/E Ratio
- PAX $28.26
- IMCR N/A
- Revenue Growth
- PAX 7.39
- IMCR 25.09
- 52 Week Low
- PAX $10.63
- IMCR $29.72
- 52 Week High
- PAX $16.16
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- PAX 52.65
- IMCR 56.41
- Support Level
- PAX $11.87
- IMCR $32.65
- Resistance Level
- PAX $12.52
- IMCR $34.78
- Average True Range (ATR)
- PAX 0.30
- IMCR 1.54
- MACD
- PAX 0.01
- IMCR 0.21
- Stochastic Oscillator
- PAX 47.37
- IMCR 74.74
About PAX Patria Investments Limited
Patria Investments Ltd is a private markets investment firm. It seeks to provide global and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.